ImmunogenX Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 6

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $60.1M

ImmunogenX General Information

Description

Operator of a biotherapeutics company intended to cater to celiac disease research. The company engages in developing latiglutenase, a potentially first-in-class, targeted, oral biotherapeutics and a digestive enzyme that degrades unintended ingestion of gluten in the body, enabling doctors to enhance the life of celiac disease patients.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 1600 Dove Street
  • Suite 330
  • Newport Beach, CA 92660
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Vertical(s)
Corporate Office
  • 1600 Dove Street
  • Suite 330
  • Newport Beach, CA 92660
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ImmunogenX Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 13-Mar-2024 $60.1M Completed Clinical Trials - Phase 3
6. Grant 08-Sep-2020 Completed Clinical Trials - General
5. Grant 01-Mar-2020 Completed Clinical Trials - General
4. Grant 01-Jan-2019 Completed Clinical Trials - General
3. Accelerator/Incubator 28-Oct-2016 Completed Clinical Trials - General
2. Early Stage VC (Series B) 23-Oct-2015 $5M $5M Completed Clinical Trials - General
1. Early Stage VC (Series A) 22-Apr-2014 Completed Clinical Trials - General
To view ImmunogenX’s complete valuation and funding history, request access »

ImmunogenX Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ImmunogenX Former Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds
National Center For Complementary And Integrative Health Government
National Institute for Allergy and Infectious Disease Government
National Institute of Diabetes and Digestive and Kidney Diseases Government
National Institutes of Health Government
Octane (California) Accelerator/Incubator
To view ImmunogenX’s complete investors history, request access »

ImmunogenX Investments (1)

ImmunogenX’s most recent deal was a Corporate Asset Purchase with Alvine Pharmaceuticals (Asstes). The deal was made on 15-Mar-2016.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Alvine Pharmaceuticals (Asstes) 15-Mar-2016 Corporate Asset Purchase Buildings and Property
To view ImmunogenX’s complete investments history, request access »

ImmunogenX FAQs

  • When was ImmunogenX founded?

    ImmunogenX was founded in 2013.

  • Where is ImmunogenX headquartered?

    ImmunogenX is headquartered in Newport Beach, CA.

  • What is the size of ImmunogenX?

    ImmunogenX has 6 total employees.

  • What industry is ImmunogenX in?

    ImmunogenX’s primary industry is Drug Discovery.

  • Is ImmunogenX a private or public company?

    ImmunogenX is a Private company.

  • What is the current valuation of ImmunogenX?

    The current valuation of ImmunogenX is .

  • What is ImmunogenX’s current revenue?

    The current revenue for ImmunogenX is .

  • How much funding has ImmunogenX raised over time?

    ImmunogenX has raised $5M.

  • Who are ImmunogenX’s investors?

    National Center For Complementary And Integrative Health, National Institute for Allergy and Infectious Disease, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, and Octane (California) have invested in ImmunogenX.

  • When was ImmunogenX acquired?

    ImmunogenX was acquired on 13-Mar-2024.

  • Who acquired ImmunogenX?

    ImmunogenX was acquired by Grid AI.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process